164 related articles for article (PubMed ID: 15655291)
1. Utilization of human liver microsomes to explain individual differences in paclitaxel metabolism by CYP2C8 and CYP3A4.
Taniguchi R; Kumai T; Matsumoto N; Watanabe M; Kamio K; Suzuki S; Kobayashi S
J Pharmacol Sci; 2005 Jan; 97(1):83-90. PubMed ID: 15655291
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics of paclitaxel in ovarian cancer patients and genetic polymorphisms of CYP2C8, CYP3A4, and MDR1.
Nakajima M; Fujiki Y; Kyo S; Kanaya T; Nakamura M; Maida Y; Tanaka M; Inoue M; Yokoi T
J Clin Pharmacol; 2005 Jun; 45(6):674-82. PubMed ID: 15901749
[TBL] [Abstract][Full Text] [Related]
3. Drug-drug Interaction between Losartan and Paclitaxel in Human Liver Microsomes with Different CYP2C8 Genotypes.
Mukai Y; Senda A; Toda T; Hayakawa T; Eliasson E; Rane A; Inotsume N
Basic Clin Pharmacol Toxicol; 2015 Jun; 116(6):493-8. PubMed ID: 25424246
[TBL] [Abstract][Full Text] [Related]
4. Paclitaxel metabolism in rat and human liver microsomes is inhibited by phenolic antioxidants.
Václavíková R; Horský S; Simek P; Gut I
Naunyn Schmiedebergs Arch Pharmacol; 2003 Sep; 368(3):200-9. PubMed ID: 12920504
[TBL] [Abstract][Full Text] [Related]
5. Metabolism of repaglinide by CYP2C8 and CYP3A4 in vitro: effect of fibrates and rifampicin.
Kajosaari LI; Laitila J; Neuvonen PJ; Backman JT
Basic Clin Pharmacol Toxicol; 2005 Oct; 97(4):249-56. PubMed ID: 16176562
[TBL] [Abstract][Full Text] [Related]
6. Characterization of human cytochrome P450 isoforms involved in the metabolism of 7-epi-paclitaxel.
Zhang YY; Liu Y; Zhang JW; Ge GB; Wang LM; Sun J; Yang L
Xenobiotica; 2009 Apr; 39(4):283-92. PubMed ID: 19350451
[TBL] [Abstract][Full Text] [Related]
7. Regioselective metabolism of taxoids by human CYP3A4 and 2C8: structure-activity relationship.
Cresteil T; Monsarrat B; Dubois J; Sonnier M; Alvinerie P; Gueritte F
Drug Metab Dispos; 2002 Apr; 30(4):438-45. PubMed ID: 11901098
[TBL] [Abstract][Full Text] [Related]
8. Different in vitro metabolism of paclitaxel and docetaxel in humans, rats, pigs, and minipigs.
Vaclavikova R; Soucek P; Svobodova L; Anzenbacher P; Simek P; Guengerich FP; Gut I
Drug Metab Dispos; 2004 Jun; 32(6):666-74. PubMed ID: 15155559
[TBL] [Abstract][Full Text] [Related]
9. Pathway-dependent inhibition of paclitaxel hydroxylation by kinase inhibitors and assessment of drug-drug interaction potentials.
Wang Y; Wang M; Qi H; Pan P; Hou T; Li J; He G; Zhang H
Drug Metab Dispos; 2014 Apr; 42(4):782-95. PubMed ID: 24476576
[TBL] [Abstract][Full Text] [Related]
10. The role of human CYP2C8 and CYP2C9 variants in pioglitazone metabolism in vitro.
Muschler E; Lal J; Jetter A; Rattay A; Zanger U; Zadoyan G; Fuhr U; Kirchheiner J
Basic Clin Pharmacol Toxicol; 2009 Dec; 105(6):374-9. PubMed ID: 19614891
[TBL] [Abstract][Full Text] [Related]
11. Effect of buffer conditions on CYP2C8-mediated paclitaxel 6α-hydroxylation and CYP3A4-mediated triazolam α- and 4-hydroxylation by human liver microsomes.
Kudo T; Ozaki Y; Kusano T; Hotta E; Oya Y; Komatsu S; Goda H; Ito K
Xenobiotica; 2016; 46(3):241-6. PubMed ID: 26290405
[TBL] [Abstract][Full Text] [Related]
12. Identification of CYP3A4 and CYP2C8 as the major cytochrome P450 s responsible for morphine N-demethylation in human liver microsomes.
Projean D; Morin PE; Tu TM; Ducharme J
Xenobiotica; 2003 Aug; 33(8):841-54. PubMed ID: 12936704
[TBL] [Abstract][Full Text] [Related]
13. CYP2C8 and CYP3A4 are the principal enzymes involved in the human in vitro biotransformation of the insulin secretagogue repaglinide.
Bidstrup TB; Bjørnsdottir I; Sidelmann UG; Thomsen MS; Hansen KT
Br J Clin Pharmacol; 2003 Sep; 56(3):305-14. PubMed ID: 12919179
[TBL] [Abstract][Full Text] [Related]
14. Relevance of nonsynonymous CYP2C8 polymorphisms to 13-cis retinoic acid and paclitaxel hydroxylation.
Rowbotham SE; Boddy AV; Redfern CP; Veal GJ; Daly AK
Drug Metab Dispos; 2010 Aug; 38(8):1261-6. PubMed ID: 20421446
[TBL] [Abstract][Full Text] [Related]
15. Association of CYP2C8, CYP3A4, CYP3A5, and ABCB1 polymorphisms with the pharmacokinetics of paclitaxel.
Henningsson A; Marsh S; Loos WJ; Karlsson MO; Garsa A; Mross K; Mielke S; Viganò L; Locatelli A; Verweij J; Sparreboom A; McLeod HL
Clin Cancer Res; 2005 Nov; 11(22):8097-104. PubMed ID: 16299241
[TBL] [Abstract][Full Text] [Related]
16. The Role of CYP2C8 and CYP2C9 Genotypes in Losartan-Dependent Inhibition of Paclitaxel Metabolism in Human Liver Microsomes.
Mukai Y; Senda A; Toda T; Eliasson E; Rane A; Inotsume N
Basic Clin Pharmacol Toxicol; 2016 Jun; 118(6):408-14. PubMed ID: 26551762
[TBL] [Abstract][Full Text] [Related]
17. Influence of Cremophor EL and genetic polymorphisms on the pharmacokinetics of paclitaxel and its metabolites using a mechanism-based model.
Fransson MN; Gréen H; Litton JE; Friberg LE
Drug Metab Dispos; 2011 Feb; 39(2):247-55. PubMed ID: 21056987
[TBL] [Abstract][Full Text] [Related]
18. Characterization of the metabolism of fenretinide by human liver microsomes, cytochrome P450 enzymes and UDP-glucuronosyltransferases.
Illingworth NA; Boddy AV; Daly AK; Veal GJ
Br J Pharmacol; 2011 Feb; 162(4):989-99. PubMed ID: 21054342
[TBL] [Abstract][Full Text] [Related]
19. Involvement of CYP3A4, CYP2C8, and CYP2D6 in the metabolism of (R)- and (S)-methadone in vitro.
Wang JS; DeVane CL
Drug Metab Dispos; 2003 Jun; 31(6):742-7. PubMed ID: 12756206
[TBL] [Abstract][Full Text] [Related]
20. Functional characterization of 12 allelic variants of CYP2C8 by assessment of paclitaxel 6α-hydroxylation and amodiaquine N-deethylation.
Tsukada C; Saito T; Maekawa M; Mano N; Oda A; Hirasawa N; Hiratsuka M
Drug Metab Pharmacokinet; 2015 Oct; 30(5):366-73. PubMed ID: 26427316
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]